Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored

Affiliations

¹ Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350001, China; Fujian Clinical Research Center for Liver and Intestinal Diseases, Fuzhou, Fujian 350001, China.
² Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350001, China; Fujian Clinical Research Center for Liver and Intestinal Diseases, Fuzhou, Fujian 350001, China. Electronic address: zhuyueyong@fjmu.edu.cn.

Comment

Xiaoning Chen et al. J Hepatol. 2024 May.

. 2024 May;80(5):e204-e205.

doi: 10.1016/j.jhep.2023.10.002. Epub 2023 Oct 11.

¹ Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350001, China; Fujian Clinical Research Center for Liver and Intestinal Diseases, Fuzhou, Fujian 350001, China.
² Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350001, China; Fujian Clinical Research Center for Liver and Intestinal Diseases, Fuzhou, Fujian 350001, China. Electronic address: zhuyueyong@fjmu.edu.cn.

No abstract available

Comment on

Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
Guerrero A, Campo LD, Piscaglia F, Scheiner B, Han G, Violi F, Ferreira CN, Téllez L, Reiberger T, Basili S, Zamora J, Albillos A; Baveno Cooperation: an EASL consortium. Guerrero A, et al. J Hepatol. 2023 Jul;79(1):69-78. doi: 10.1016/j.jhep.2023.02.023. Epub 2023 Feb 28. J Hepatol. 2023. PMID: 36858157